Martin Edwards is Director at Verona Pharma plc (VRNA). They have made 3 open-market trades across 2 companies since 2021, most recently 2025-10-07.
CIK 0001640073
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $173K since 2023, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRNA | SELL | 2025-08-01 | 2025-08-05 | $13.14 | $284K | +0.0% | +0.9% | N/A |
| VRNA | BUY | 2023-11-20 | 2023-11-22 | $1.84 | $124K | -5.2% | +23.4% | +19.5% |
| MORF | BUY | 2023-11-13 | 2023-11-15 | $20.54 | $49K | -1.7% | +30.2% | +56.2% |
| VRNA | SELL · 10b5-1 | 2021-05-04 | 2021-05-05 | $0.84 | $10K | -9.4% | -4.8% | -3.0% |
| VRNA | SELL · 10b5-1 | 2021-02-01 | 2021-02-03 | $0.99 | $14K | +3.5% | +4.9% | -19.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.